araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

Summary: To understand 295 gene mutation mutation status (include EGFR, HER2, KRAS, BRAF, PIK3CA,ect) by deep sequencing in Chinese patients with pulmonary adenocarcinoma and their relationships with the patients' clinical features (including sex, age, smoking history and adenocarcinoma subtype), specify the predictive significance of the genes mutations for new targeted therapies in NSCLC patients, and better understand the molecular mechanism drug resistance to EGFR-TKIs.

Detailed description: This study is prospective to identify biomarkers to resistant to afatinib，gefitinib and erlotinib in non-small cell lung cancer patients. Mutations of whole exon of 295 gene are analysed by deep sequencing in Chinese patients with non-small cell lung cancer and their relationships with the patients' clinical features (including sex, age, smoking history and adenocarcinoma subtype), specify the predictive significance of the genes mutations for new targeted therapies in NSCLC patients, and better understand the molecular mechanism drug resistance to EGFR-TKIs.

Eligibility: Inclusion Criteria:
  -  Age>18 years,both male and female
  -  Histologically confirmed patients with pulmonary adenocarcinoma (Stage I-IV)
  -  ECOG 0-2
  -  Patients with enough paraffin tissue specimens or fresh tissue for detection
  -  Quality of the DNA extracted from the tissue samples ensures that the DNA can be used in DNA sequencing
  -  Subjects who provide detailed clinical and follow-up information
  Exclusion Criteria:
  -  Patients with other tumors
  -  Patients suffering from other serious diseases like infectious diseases (viral hepatitis, HIV,etc)
  -  Pregnant women shall be excluded

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms

Summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Rectal Neoplasms.

Detailed description: By enrolling patients with unresectable Rectal Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Rectal Neoplasms.

Eligibility: Inclusion Criteria:
  -  Rectal Neoplasms diagnosed by positive biopsy or non-invasive criteria,
  -  Not suitable for surgical resection,
  -  Eastern Cooperative Oncology Group (ECOG) score of 0-1,
  -  A prothrombin time ratio > 50%,
  -  Platelet count > 80x10^9/L,
  -  Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
  -  Able to comprehend and willing to sign the written informed consent form (ICF),
  -  Have a life expectancy of at least 3 months.
  Exclusion Criteria:
  -  Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
  -  Any active implanted device (eg Pacemaker),
  -  Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
  -  Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
  -  Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms

Summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Uterine Cervical Neoplasms.

Detailed description: By enrolling patients with unresectable Uterine Cervical Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Uterine Cervical Neoplasms.

Eligibility: Inclusion Criteria:
  -  Uterine Cervical Neoplasms diagnosed by positive biopsy or non-invasive criteria,
  -  Not suitable for surgical resection,
  -  Eastern Cooperative Oncology Group (ECOG) score of 0-1,
  -  A prothrombin time ratio > 50%,
  -  Platelet count > 80x10^9/L,
  -  Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
  -  Able to comprehend and willing to sign the written informed consent form (ICF),
  -  Have a life expectancy of at least 3 months.
  Exclusion Criteria:
  -  Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
  -  Any active implanted device (eg Pacemaker),
  -  Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
  -  Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
  -  Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms

Summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Stomach Neoplasms.

Detailed description: By enrolling patients with unresectable Head and Stomach adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Stomach Neoplasms.

Eligibility: Inclusion Criteria:
  -  Stomach Neoplasms diagnosed by positive biopsy or non-invasive criteria,
  -  Not suitable for surgical resection,
  -  Eastern Cooperative Oncology Group (ECOG) score of 0-1,
  -  A prothrombin time ratio > 50%,
  -  Platelet count > 80x10^9/L,
  -  Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
  -  Able to comprehend and willing to sign the written informed consent form (ICF),
  -  Have a life expectancy of at least 3 months.
  Exclusion Criteria:
  -  Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
  -  Any active implanted device (eg Pacemaker),
  -  Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
  -  Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
  -  Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms

Summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Laryngeal Neoplasms.

Detailed description: By enrolling patients with unresectable Laryngeal Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Laryngeal Neoplasms.

Eligibility: Inclusion Criteria:
  -  Laryngeal Neoplasms diagnosed by positive biopsy or non-invasive criteria,
  -  Not suitable for surgical resection,
  -  Eastern Cooperative Oncology Group (ECOG) score of 0-1,
  -  A prothrombin time ratio > 50%,
  -  Platelet count > 80x10^9/L,
  -  Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
  -  Able to comprehend and willing to sign the written informed consent form (ICF),
  -  Have a life expectancy of at least 3 months.
  Exclusion Criteria:
  -  Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
  -  Any active implanted device (eg Pacemaker),
  -  Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
  -  Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
  -  Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency

Summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for Lung Neoplasms accompanied by Respiratory Function Insufficiency.

Detailed description: By enrolling patients with Lung Neoplasms accompanied by Respiratory Function Insufficiency adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for Lung Neoplasms accompanied by Respiratory Function Insufficiency.

Eligibility: Inclusion Criteria:
  -  Lung Neoplasms Accompanied by Respiratory Function Insufficiency diagnosed by positive biopsy or non-invasive criteria,
  -  Not suitable for surgical resection,
  -  Eastern Cooperative Oncology Group (ECOG) score of 0-1,
  -  A prothrombin time ratio > 50%,
  -  Platelet count > 80x10^9/L,
  -  Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
  -  Able to comprehend and willing to sign the written informed consent form (ICF),
  -  Have a life expectancy of at least 3 months.
  Exclusion Criteria:
  -  Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
  -  Any active implanted device (eg Pacemaker),
  -  Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
  -  Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
  -  Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms

Summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Renal Pelvic and Ureteral Neoplasms.

Detailed description: By enrolling patients with unresectable Renal Pelvic and Ureteral Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Renal Pelvic and Ureteral Neoplasms.

Eligibility: Inclusion Criteria:
  -  Renal Pelvic and Ureteral Neoplasms diagnosed by positive biopsy or non-invasive criteria,
  -  Not suitable for surgical resection,
  -  Eastern Cooperative Oncology Group (ECOG) score of 0-1,
  -  A prothrombin time ratio > 50%,
  -  Platelet count > 80x10^9/L,
  -  Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
  -  Able to comprehend and willing to sign the written informed consent form (ICF),
  -  Have a life expectancy of at least 3 months.
  Exclusion Criteria:
  -  Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
  -  Any active implanted device (eg Pacemaker),
  -  Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
  -  Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
  -  Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Evaluation of 4th Generation Bipolar Radiofrequency Endometrial Ablation Device

Summary: All women presenting to the gynaecology outpatient clinic with heavy menstrual bleeding (HMB) in the absence of recognizable pelvic pathology, as determined by one or all of a normal pelvic ultrasound, hysteroscopy and / or endometrial biopsy, refractory to medical therapy that persists despite treatment with recommended pharmacological agents(1,2), who have no desire to preserve their fertility and are willing to have an endometrial ablation will be invited to participate. Eligible women with HMB will undergo radiofrequency G4 endometrial ablation in either an inpatient or outpatient setting according to their preference.
  Outcomes will be assessed by administering postal questionnaires to measure menstrual bleeding symptoms including rates of amenorrhoea, dysmenorrhoea and life quality at baseline and at 6, and 12 months after ablative treatment. After the main study, there will be an additional evaluation of the long-term effects of outpatient ablative treatments of the endometrium by postal survey at 5 years.


Eligibility: Inclusion Criteria:
  1. Women with no desire to preserve their fertility who have heavy menstrual bleeding without organic pathology (DUB) of more than six months duration
  2. Associated functional disability (negative impact on life quality).
  3. Lack of response to medical treatment.
  4. Prepared to undergo surgical treatment without general anaesthesia
  Exclusion Criteria:
  1. Women under 25 years
  2. Suspected genital tract infection
  3. Uterine pathology including endometrial pathology on endometrial biopsy (e.g. endometrial hyperplasia or carcinoma) and structural lesions (e.g. uterine malformations, adhesions, polyps, submucous fibroids or extracavity fibroids > 3cm in diameter) as identified on pelvic ultrasound and/or outpatient hysteroscopy.
  4. Uterine cavity length >11cm
  5. Adnexal pathology
  6. Previous open myomectomy or endometrial ablation / resection and classical caesarian section
  7. Patients considered vulnerable (e.g. current mental illness, emotionally labile, learning difficulties, immaturity)

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors

Summary: This study is a single-arm, phase II study of sirolimus in patient with PIK3CA mutation and PIK3CA amplication Refractory solid tumors.
  sirolimus 1mg will be administered orally qd daily.
  To investigate the efficacy of sirolimus in patients with PIK3CA mutation and PIK3CA amplication Refractory solid tumors.


Eligibility: Inclusion Criteria:
  1. Provision of fully informed consent prior to any study specific procedures.
  2. Patients must be ≥20 years of age.
  3. PIK3CA amplification and/or PIK3CA mutation Refractory Solid Tumors.
  4. ECOG performance status 0-2.
  5. Have measurable or evaluated disease based on RECIST1.1. as determined by investigator.
  6. Adequate Organ Function Laboratory Values
  -  Absolute neutrophil count ≥ 1.5 x 109/L, Hemoglobin ≥ 9g/dL, Platelets ≥ 100 x 109/L
  -  bilirubin ≤ 1.5 x upper limit of normal AST/ALT ≤ 2.5 x upper limit of normal (5.0 X upper limit of normal , for subjects with liver metastases)
  -  creatinine ≤1.5 x UNL
  7. Patients of child-bearing potential should be using adequate contraceptive measures (two forms of highly reliable methods) should not be breast feeding and must have a negative pregnancy test prior to start of dosing.
  8. Adequate heart function.
  Exclusion Criteria:
  1. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤5 years.
  2. Has known active central nervous system (CNS) metastases.
  3. Has an active infection requiring systemic therapy.
  4. Pregnancy or breast feeding
  5. Patients with cardiac problem.

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Summary: This is a pilot study of Pazopanib in patients with FGFR2 Amplification or FGFR2 mutation Refractory solid tumors.
  This study is a single-arm, pilot study of Pazopanib in subjects with Refractory solid tumors harboring FGFR2 Amplification or FGFR2 mutation Pazopanib 800mg will be administered orally once a day 28 days.Study treatment will be continued until objective disease progression.
  To investigate the efficacy of Pazopanib in subjects with Refractory solid tumors harboring FGFR2 Amplification or FGFR2 mutation.


Eligibility: Inclusion Criteria:
  1. Provision of fully informed consent prior to any study specific procedures.
  2. Patients must be ≥20 years of age.
  3. FGFR2 amplification or FGFR2 mutation Refractory Solid Tumors that has recurred or progressed following standard therapy, or that has not responded to standard therapy, or for which there is no standard therapy.
  4. ECOG performance status 0-2.
  5. Have measurable or evaluated disease based on RECIST1.1. as determined by investigator.
  6. Adequate Organ Function Laboratory Values
  -  Absolute neutrophil count ≥ 1.5 x 109/L, Hemoglobin ≥ 9g/dL, Platelets ≥ 100 x 109/L
  -  bilirubin ≤ 1.5 x upper limit of normal AST/ALT ≤ 2.5 x upper limit of normal (5.0 X upper limit of normal , for subjects with liver metastases)
  -  creatinine ≤1.5 x UNL
  7. Patients of child-bearing potential should be using adequate contraceptive measures (two forms of highly reliable methods) should not be breast feeding and must have a negative pregnancy test prior to start of dosing.
  8. Adequate heart function.
  Exclusion Criteria:
  1. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤5 years.
  2. Has known active central nervous system (CNS) metastases.
  3. Has an active infection requiring systemic therapy.
  4. Pregnancy or breast feeding
  5. Patients with cardiac problem.
  6. Any previous treatment with Pazopanib.

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Summary: The primary objectives of the Phase I study 15404 are to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given once every 3 weeks in Japanese subjects with advanced, refractory solid tumors.
  The secondary objectives are to investigate the efficacy, biomarkers and immunogenicity.


Eligibility: Inclusion Criteria:
  -  Japanese subjects ≥ 20 years of age
  -  ECOG Performance Status of 0 to 1
  -  Life expectancy of at least 12 weeks
  -  Subjects with advanced, histologically or cytologically confirmed solid tumors, not amenable to any standard therapy, have no standard therapy available
  -  Subjects whose fresh or archival tumor tissues are available
  -  Measurable disease with at least one lesion that can be accurately measured in at least one dimension according to RECIST criteria (Version 1.1 or modified version)
  -  Adequate bone marrow, liver, and renal function
  Exclusion Criteria:
  -  Anticancer chemotherapy, experimental cancer therapy, or immunotherapy within 2 weeks of start of the first dose
  -  Impaired cardiac function or clinically significant cardiac disease (i.e., congestive heart failure (CHF) NYHA Class III or IV)
  -  Myocardial infarction or onset of unstable angina < 3 months prior to general screening
  -  Cardiac arrhythmias in the electrocardiogram that would interfere with QT/QTc interval measurement (LBBB (left bundle branch block), AV block, atrial fibrillation)
  -  QTc >470 ms, derived as the average of the 3 values measured by the ECG recorder's algorithm on the ECG triplicate
  -  LVEF (left ventricular ejection fraction) <50 %
  -  Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 90 mmHg, despite optimal medical management
  -  Known human immunodeficiency virus (HIV) infection
  -  Subjects with an active hepatitis B or C infection requiring treatment
  -  Personal or family history of Long QT Syndrome (LQTS)
  -  Subject with clinically significant eye disorders

Relevance to patient case: not relevant
Patient case: 58-year-old female with endometrial cancer; genetic feature: PIK3R1

Clinical trial: The Feasibility Study of the Li Brush for the Screening of Endometrial Cancer in the Postmenopausal Period

Summary: Investigators aim to collect endometrial sampling with Li Brush among target population who have risks for endometrial neoplasm, then Fractional curettage should performed with these participants, investigators intend to compare the pathological diagnosis results of cytology and fractional curettage to evaluate the sensitivity of Li Brush and investigators expect that the brush can be used for screening of endometrial cancer in the postmenopausal period in the clinic.

Detailed description: Investigators screen the suitable participants according to the inclusion and exclusion standards, and then collect their endometrial sampling with Li Brush. Pathologists will help to decide the cytology obtained by Li Brush and histology diagnosis of the endometrial sampling. Comparing the pathological diagnosis results of cytology and histology, investigators want to prove the feasibility of cytology diagnosis of endometrial cancer in the postmenopausal period, as the same time, investigators intend to evaluate the possible factors that affecting the precision of Li Brush for endometrial cancer in the postmenopausal period.

Eligibility: Inclusion Criteria:
  1. Postmenopausal abnormal uterine bleeding;
  2. Ultrasound of the pelvic showed thickened endometrial ( usually more than 5mm) ;
  3. Family history of endometrial cancers;
  4. Other participants with risks for endometrial cancer (such as fat, Lynch Syndrome and so on)
  Exclusion Criteria:
  1. Cervical cancer;
  2. Fever (body's temperature is higher than 37.5 degrees );
  3. Vaginitis (excluding atrophic vaginitis);
  4. Patients who cannot bear the operation;
  5. Coagulation disorders;
  6. Pregnancy and suspected pregnancy.

Relevance to patient case: not relevant